Page
Advancing Biosimilars and Optimizing Psoriasis Treatment: Highlights from the 2025 ICD Symposium.
Experts from across five continents discuss regional biosimilar uptake and practical strategies for optimizing…
Experts from across five continents discuss regional biosimilar uptake and practical strategies for optimizing…
View ReportThe 2025 AAD Annual Meeting featured important updates on psoriasis therapies, comorbidities, and late-breaking…
View ReportDr. Satveer Mahil leads a panel of global psoriasis experts as they answer questions from the second and third parts of…
Watch VideoThe 33rd Annual EADV Congress in Amsterdam featured updates on psoriasis care, including highlights from the IPC…
Read MoreThis report from the 53rd Annual ESDR Meeting in Lisbon covers key presentations on psoriasis, including updates from…
Read MoreThe 53rd Annual European Society for Dermatological Research (ESDR) Meeting was held in Lisbon, Portugal, from…
View ReportEUROPEAN SOCIETY FOR DERMATOLOGICAL RESEARCH ANNUAL MEETING (ESDR) | LISBON, PORTUGAL Program chairs: Johann…
EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY (EADV) | AMSTERDAM, NETHERLANDS Program chairs: Lone Skov, Denmark and…
The spread of COVID-19 in early 2020 brought many concerns and questions about COVID-19 and psoriasis. To help address…
Read MoreIn the final webinar in the series, we will explore lessons from the SARS-CoV-2 pandemic and how we can prepare for…
Watch VideoWatch Video
The Psoriasis: from Gene to Clinic International Congress provides a forum for psoriasis experts from around the world…
Read MoreThe ESDR congress included many noteworthy psoriasis presentations from both IPC councilors and experts from around the…
Read MoreSatveer Mahil joins the group of respected IPC psoriasis experts who are working to advance knowledge and enhance the…
Read MoreHeld virtually on December 11 due to the Coronavirus Pandemic, the 2020 IPC Think Tank convened more than 100…
Read MoreThe registries, PsoProtect and PsoProtectMe, aim to help health care workers understand how the novel virus affects…
Read MoreView Report
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.
In this article, IPC Board Member Lluís Puig, MD, PhD, gives his expert commentary on two randomized trials showing that ixekizumab plus tirzepatide outperforms ixekizumab alone for skin clearance, joint control, and weight loss in psoriasis and PsA.
IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.
Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.
IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.
In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.